Cancer clinical trials in the region Grand Est
294 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lymphoma
Brain tumors / Central nervous system tumors
#NCT07015242
#2025-521144-38-00
Required histologic types
B cell lymphoma
Other primary CNS tumor
Required histologic sub types
Primary cerebral lymphoma
Primary CNS lymphoma
Required central nervous system lesions
Actives
Required number of previous lines of therapy
None
Excluded previous treatments
Car-T
Allogeneic stem cell transplant
12 recruiting sites
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
Endometrial cancer
Sarcoma and GIST
#NCT03624244
Required histologic types
Soft tissue sarcoma
Required histologic sub types
Other
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
19 recruiting sites
Centre Léon Bérard
Phase 2
Pancreas cancer
#NCT07483983
#2025-522533-54-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12D
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Stomach and esophageal cancer
#NCT06059495
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Radiotherapy
11 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2
Lung cancer
#NCT06712316
#2024-515764-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
24 recruiting sites
BioNTech SE
Phase 2
Lung cancer
#NCT06656598
#2024-517316-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
25 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2
Lung cancer
#NCT06840834
#2024-519052-82-00
Required histologic types
Mesothelium
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
17 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Lymphoma
#NCT06558604
#2023-506706-40-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
30-50 ml/min
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy
Targeted therapy
Excluded previous treatments
Bispecific T-cell engager antibodies
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)